casdatifan (AB521) / Arcus Biosci 
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
casdatifan (AB521) / Arcus Biosci
STELLAR-009, NCT06191796: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors

Active, not recruiting
1/2
25
US
zanzalintinib, XL092, AB521, Nivolumab, OPDIVO®
Exelixis, Arcus Biosciences, Inc.
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
01/26
01/27
NCT05117554: Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Completed
1
70
Europe
casdatifan, AB521, Placebo, Midazolam
Arcus Biosciences, Inc.
Healthy Participants
02/23
02/23
NCT05999513: A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Completed
1
24
US
casdatifan, AB521
Arcus Biosciences, Inc.
Healthy Participants
10/23
10/23
ARC-20, NCT05536141: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Recruiting
1
302
US, RoW
casdatifan, AB521, Cabozantinib
Arcus Biosciences, Inc.
Clear Cell Renal Cell Carcinoma, Solid Tumors
01/26
01/26

Download Options